Condition: Gastric Cancer · Peritoneal Carcinomatosis · Sponsor: University of Chicago
To assess if PD-L1 expression can be upregulated in peritoneal metastases from gastric cancer after the administration of HIPEC with greater frequency compared to systemic chemotherapy alone
This description comes directly from the study's public registry record.
Cancer Clinical Trials Office · 1-855-702-8222 · cancerclinicaltrials@bsd.uchicago.edu
Always discuss trial participation with your own doctor first.
| University of Chicago | Chicago, Illinois, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04107077